Bone Marrow News and Research RSS Feed - Bone Marrow News and Research

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
Researchers show how a new drug speeds tissue regeneration in animal models

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality. [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently mutated in a common form of adult leukemia and is likely necessary to bring about the full-blown disease. [More]
Study reveals how immune cells are programmed to repair or protect the body

Study reveals how immune cells are programmed to repair or protect the body

An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body. [More]
Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

A Creighton University researcher has received a National Institutes of Health grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure. [More]
Researchers identify potential treatment option for childhood leukemia

Researchers identify potential treatment option for childhood leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade. [More]
US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure. [More]
Massey researchers aim to develop models that can predict complications from stem cell transplantation

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. [More]
‘VascuBone Toolbox’ provides components required for customised vascularised bone implant

‘VascuBone Toolbox’ provides components required for customised vascularised bone implant

The EU project VascuBone was coordinated by the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and has reached the end of a 5-year funding period. [More]
Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee. [More]
Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States. [More]
Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade. [More]
Gold nanoparticles with functional surfaces regulate osteogenic differentiation of stem cells

Gold nanoparticles with functional surfaces regulate osteogenic differentiation of stem cells

Tissue Regeneration Materials Unit (Guoping Chen, Unit Director) at the International Center for Materials Nanoarchitectonics (MANA) (Masakazu Aono, Director General, MANA), NIMS (Sukekatsu Ushioda, President) successfully developed gold nanoparticles that have functional surfaces and act on osteogenic differentiation of stem cells. [More]
Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD. [More]
Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow. [More]
Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). [More]
Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. [More]
Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Secret to the life-long activity of a stem cell niche

Secret to the life-long activity of a stem cell niche

The roots of a plant are constantly growing, so that they can provide the plant with water and minerals while also giving it a firm anchor in the ground. Responsible for these functions are pluripotent stem cells. In order to avoid differentiation and to remain pluripotent, these stem cells are dependent on signals from their neighbouring cells. [More]
Advertisement
Advertisement